Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

This study is testing whether adding a drug called bicalutamide (a hormone-blocking drug) to sunitinib (a targeted cancer drug) can help treat kidney cancer (renal cell carcinoma) that has stopped responding to other targeted therapies. **You may be eligible if...** - You are 18 years old or older - You have kidney cancer that is measurable on imaging - Your cancer has stopped responding to prior targeted therapies (TKIs) - Your overall health status is acceptable (ECOG 0–2) - Your organ function (blood counts, liver, kidneys) is adequate - You are willing to use contraception during and for 4 months after treatment **You may NOT be eligible if...** - You have active brain metastases - You have an immune system disorder or are on immunosuppressive drugs - You have active tuberculosis, hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding - You received a live vaccine within the last 30 days - You have another active or progressing cancer Talk to your doctor to see if this trial is right for you.